Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kyprolis head-to-head PhIII against Velcade may push Onyx closer to acquistion

This article was originally published in Scrip

Executive Summary

Onyx Pharmaceuticals has started its third Phase III clinical trial, the first that pits its proteasome inhibitor Kyprolis (carfilzomib) against Millennium's Velcade (bortezomib) in the treatment of multiple myeloma, the drug's first head-to-head comparison. Some analysts believe that if Kyprolis outperforms Velcade, and if Kyprolis' current NDA is approved by the US FDA, Onyx could become of great interest to acquisitive pharma companies.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC017972

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel